Zhejiang East Asia Pharmaceutical Co., Ltd. (605177.SS)
CNY 19.91
(1.01%)
CNY 19.91
(1.01%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 348.75 Million CNY | 34.26% |
| 2022 | 269.15 Million CNY | 33.87% |
| 2021 | 201.05 Million CNY | -32.87% |
| 2020 | 299.49 Million CNY | -13.39% |
| 2019 | 345.79 Million CNY | 22.1% |
| 2018 | 283.2 Million CNY | 28.5% |
| 2017 | 220.4 Million CNY | -2.66% |
| 2016 | 226.41 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 68.94 Million CNY | -23.02% |
| 2024 Q1 | 89.56 Million CNY | -9.44% |
| 2024 Q3 | 88.37 Million CNY | 28.18% |
| 2023 Q4 | 98.89 Million CNY | 0.11% |
| 2023 FY | 361.35 Million CNY | 34.26% |
| 2023 Q3 | 98.78 Million CNY | 21.26% |
| 2023 Q2 | 81.46 Million CNY | -0.92% |
| 2023 Q1 | 82.21 Million CNY | -4.1% |
| 2022 FY | 269.15 Million CNY | 33.87% |
| 2022 Q3 | 67.72 Million CNY | 28.43% |
| 2022 Q2 | 52.73 Million CNY | -16.24% |
| 2022 Q1 | 62.95 Million CNY | 13.54% |
| 2022 Q4 | 85.73 Million CNY | 26.59% |
| 2021 Q2 | 52.23 Million CNY | -17.9% |
| 2021 Q1 | 63.62 Million CNY | 23.01% |
| 2021 FY | 201.05 Million CNY | -32.87% |
| 2021 Q4 | 55.44 Million CNY | 86.37% |
| 2021 Q3 | 29.75 Million CNY | -43.04% |
| 2020 FY | 299.49 Million CNY | -13.39% |
| 2020 Q4 | 51.72 Million CNY | -8.21% |
| 2020 Q3 | 56.34 Million CNY | -60.25% |
| 2020 Q2 | 141.73 Million CNY | 185.21% |
| 2020 Q1 | 49.69 Million CNY | -46.17% |
| 2019 Q4 | 92.32 Million CNY | 9.34% |
| 2019 Q3 | 84.43 Million CNY | 0.0% |
| 2019 FY | 345.79 Million CNY | 22.1% |
| 2018 FY | 283.2 Million CNY | 28.5% |
| 2017 FY | 220.4 Million CNY | -2.66% |
| 2016 FY | 226.41 Million CNY | 0.0% |